Latest Pseudobulbar affect Stories
NUEDEXTA recommended for the treatment of PBA, irrespective of neurologic cause ALISO VIEJO, Calif., April 26, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for NUEDEXTA(®) (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect (PBA),...
Veterans with TBI at Risk for Debilitating Condition, Pseudobulbar Affect, Causing Uncontrollable Crying and/or Laughing Outbursts ALISO VIEJO, Calif., March 6, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) in collaboration with the Department of Veterans Affairs (VA) and United BioSource Corporation (UBC) today announced a pilot study to screen for pseudobulbar affect (PBA) symptoms in approximately 1,000 veterans with traumatic brain injury (TBI) . According to...
ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing...
ALISO VIEJO, Calif., Dec. 12, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve months ended September 30, 2012. Quarterly Financial Highlights Gross and net NUEDEXTA® sales of $15.4 million and $12.4 million, respectively, an increase of 26% and 23% versus the previous quarter Total company net revenue of $13.5 million Cash, cash equivalents, and restricted investments of $72.1 million as of September 30,...
ALISO VIEJO, Calif., Nov. 27, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary results for the quarter ended September 30, 2012. Financial Update Based on preliminary results for the fourth fiscal quarter ended September 30, 2012, Avanir estimates: Gross revenue for NUEDEXTA® of $15.4 million, representing an increase of approximately 26% over the prior quarter Total operating expenses, excluding cost of product sales and non-cash...
Campaign Ambassador Shares Personal Fight Against Pseudobulbar Affect, a Condition that Causes Sudden and Inappropriate Outbursts CENTENNIAL, Colo., Oct. 8, 2012 /PRNewswire-USNewswire/ -- Sonja Frazier, 65, suffered her first stroke in June 2005, while at work. Because she received immediate medical attention, Sonja recovered well, but after her stroke, she was more emotional, tearing up and crying like never before. (Photo: http://photos.prnewswire.com/prnh/20121008/DC88497...
ALISO VIEJO, Calif., Sept. 20, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several business updates. The highlights are being provided in connection with the company's presentation today at the UBS Global Life Sciences Conference in New York City. Highlights include: Exceeding 10,000 total NUEDEXTA® prescriptions for the month of August. NUEDEXTA prescriptions of 10,710 in August represent 9% growth over the month of July. August monthly...
ALISO VIEJO, Calif., Sept. 5, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that Advances in Therapy published results from a U.S. survey conducted by Harris Interactive, comparing Quality of Life (QOL), Quality of Relationships (QOR), health status and daily function of neurologic patients with and without symptoms of pseudobulbar affect (PBA). A link to the online article can be accessed at http://www.advancesintherapy.com/. "The results from...
ALISO VIEJO, Calif., Sept. 4, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. "Alzheimer's disease can cause a person to exhibit marked behavioral changes that are difficult for caregivers to manage. These symptoms can include agitation, hostility, anger, and...
